Effects of Suramin on Polycystic Kidney Disease in a Mouse Model of Polycystin-1 Deficiency.
Ontology highlight
ABSTRACT: The aberrant activation of the purinergic signaling pathway has been shown to promote cyst growth and fluid secretion in autosomal dominant polycystic kidney disease (ADPKD). Suramin is an anti-parasitic drug that has strong anti-purinergic properties. Whether suramin could have a therapeutic effect on ADPKD has not been fully investigated. We examined the effect of suramin on cyst progression in a Pkd1 microRNAs transgenic mouse model that presented stable Pkd1 knockdown and moderate disease progression. The Pkd1-deficient mice were treated with suramin (60 mg/kg) by intraperitoneal injection twice a week from postnatal days 35 to 90. Kidney-to-body weight ratios, cyst indices, and blood urea nitrogen (BUN) levels were measured. Cell proliferation and macrophage infil
SUBMITTER: Chang MY
PROVIDER: S-EPMC9369130 | biostudies-literature | 2022 Jul
REPOSITORIES: biostudies-literature
ACCESS DATA